摘要
目的:探讨醋酸甲羟孕酮片联合新辅助化疗对子宫内膜癌患者肿瘤标志物的影响。方法:采用随机数字表法将我院2017年3月—2019年3月收治的子宫内膜癌患者100例分为两组,各50例。对照组给予新辅助化疗,观察组给予醋酸甲羟孕酮片(250 mg,qd)联合新辅助化疗,比较分析两组肿瘤标志物[基质金属蛋白酶(Matrix metalloprotein,MMP)-9、血管内皮生长因子(vascular endothelial growth factor,VEGF)、人附睾蛋白4(human epididymis protein 4,HE4)、糖类抗原(carbonhydrate antigen,CA)19-9、CA125]水平。结果:治疗前两组MMP-9、VEGF、HE4、CA19-9及CA125水平比较,差异无统计学意义(P>0.05);化疗2周后观察组MMP-9、VEGF、HE4、CA19-9及CA125水平均低于对照组,差异有统计学意义(P<0.05);两组毒副反应发生率比较,差异无统计学意义(P>0.05)。结论:醋酸甲羟孕酮片联合新辅助化疗治疗可降低子宫内膜癌患者的肿瘤标志物水平,促进患者恢复。
Objective:To investigate the effect of medroxyprogesterone acetate tablets combined with neoadjuvant chemotherapy on tumor markers in patients with endometrial cancer.Methods:100 patients with endometrial cancer admitted to our hospital from March 2017 to March 2019 were randomly divided into two groups:a control group and an observation group,50 cases each.The patients in the control group received neoadjuvant chemotherapy,and the patients in the observation group received medroxyprogesterone acetate tablets(250 mg,qd)combined with neoadjuvant chemotherapy.The levels of tumor markers[matrix metalloproteinase(MMP)-9,vascular endothelial growth factor(VEGF),human epididymis protein 4(HE4),carbohydrate antigen(CA)19-9,CA125]in the two groups were compared and analyzed.Results:There were no statistically significant differences in the levels of MMP-9,VEGF,HE4,CA19-9 and CA125 before treatment between the two groups(P>0.05).After 2 weeks of chemotherapy,the levels of MMP-9,VEGF,HE4,CA19-9 and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion:Medroxyprogesterone acetate tablets combined with neoadjuvant chemotherapy can reduce the levels of tumor markers in patients with endometrial cancer and promote recovery.
作者
翟高科
Zhai Gao-ke(Department of Obstetrics and Gynecology,Sanmenxia Third People’s Hospital,Sanmenxia Henan 472143,China)
出处
《中国合理用药探索》
CAS
2019年第10期52-54,共3页
Chinese Journal of Rational Drug Use
关键词
子宫内膜癌
醋酸甲羟孕酮片
新辅助化疗
肿瘤标志物
Endometrial Cancer
Medroxyprogesterone Acetate Tablet
Neoadjuvant Chemotherapy
Tumor Marker
